注意！这些基因的变异影响免疫疗效！(5)

1.Peng, W., Chen, J.Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M.T., Xu, C., McKenzie, J.A., Zhang, C., Liang, X., et al. (2016). Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov 6, 202-216. [转载出处：www.ii77.com]

2.Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

3.  Gainor J F, Shaw A T, Sequist L V, et al. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer (NSCLC): A Retrospective Analysis[J]. Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2016, 22(18):4585.

4. George S, Miao D, Demetri G D, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.[J]. Immunity, 2017, 46(2):197-204.

Kato S, Goodman A M, Walavalkar V, et al. Hyper-progressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.[J]. Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2017, 23(15):4242